EUVIMEDScopri EUVIMED
Crossref

Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients

Kennedy Concannon iD, Rachel Huntsman iD, Kristin Cole iD, Cassie Kennedy iD, Andrew Rosenbaum iD, Adley Lemke iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70165 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Kennedy Concannon and 5 co-authors. Institution: Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA. Major MEDLINE topics: Pyridones, Pyrazoles, Itraconazole, Heart Transplantation. 26 references. Funded by: Mayo Midwest Pharmacy Research Committee.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Itraconazole and posaconazole are frequently prescribed following transplantation to prevent and treat fungal infections. Navigating drug interactions is challenging due to these agents’ potent CYP3A4 inhibition, and literature describing concurrent apixaban, a CYP3A4 substrate, is limited. This retrospective study of cardiothoracic transplant recipients evaluates the impact of itraconazole and posaconazole on apixaban exposure and reports clinical outcomes from routine apixaban dose reduction. Institutional practice reduces apixaban to 2.5 mg twice daily with itraconazole or posaconazole and obtains apixaban therapeutic drug monitoring (TDM), expected range 34–230 ng/mL. Eighteen levels collected in 15 patients on itraconazole displayed a median [IQR] apixaban trough of 143 ng/mL [95–195]. Fifteen levels collected in 13 patients on posaconazole displayed a median [IQR] apixaban trough of 124 ng/mL [93–174]. Two major bleed events, three VTE, two stroke, and eight instances of clot resolution were identified. Reduced‐dose apixaban resulted in apixaban exposure similar to normal dosing in the general population. Apixaban TDM is encouraged for individualized dosing when administered with itraconazole and posaconazole.

Subjects

MeSH terms (MEDLINE)

PyridonesPyrazolesItraconazoleHeart TransplantationAntifungal AgentsTriazolesMycosesPostoperative ComplicationsGraft RejectionHumansMaleRetrospective StudiesMiddle AgedFemaleFollow-Up StudiesPrognosisDrug InteractionsAgedTransplant RecipientsAdultDrug MonitoringGraft Survival

Author keywords

apixabanazole antifungalcardiothoracic transplantdrug interactiontherapeutic drug monitoring

Substances

apixabanPyridonesPyrazolesItraconazoleposaconazoleAntifungal AgentsTriazoles

Authors and institutions

  • Department of Pharmacy, Mayo Clinic Hospital, Rochester, Minnesota, USA.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic Hospital, Rochester, Minnesota, USA.
  • Division of Pulmonary and Critical Care Medicine, Mayo Clinic Hospital, Rochester, Minnesota, USA.
  • Division of Cardiovascular Diseases, Mayo Clinic Hospital, Rochester, Minnesota, USA.

ORCID profiles: Kennedy Concannon, Rachel Huntsman, Kristin Cole, Cassie Kennedy, Andrew Rosenbaum, Adley Lemke

Funding

  • Mayo Midwest Pharmacy Research Committee

Cite

APA

Concannon, K., Huntsman, R., Cole, K., Kennedy, C., Rosenbaum, A., & Lemke, A. (2025). Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70165

Vancouver

Concannon K, Huntsman R, Cole K, Kennedy C, Rosenbaum A, Lemke A. Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70165

BibTeX
@article{Concannon2025,
  author = {Concannon, Kennedy and Huntsman, Rachel and Cole, Kristin and Kennedy, Cassie and Rosenbaum, Andrew and Lemke, Adley},
  title = {Concurrent Apixaban With Itraconazole or Posaconazole Pharmacokinetic and Clinical Outcome Evaluation in Cardiothoracic Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70165}
}
Start for free →